Cargando…

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

BACKGROUND: There is no clear standard of care for advanced/recurrent endometrial cancer (EC) following platinum-based therapy. Dostarlimab is approved for patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced/recurrent EC. This indirect treatment comparison...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathews, Cara, Lorusso, Domenica, Coleman, Robert L, Boklage, Susan, Garside, Jamie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Gynecologic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732237/ https://www.ncbi.nlm.nih.gov/pubmed/36124638 http://dx.doi.org/10.1093/oncolo/oyac188

Ejemplares similares

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
Publicado: (2022)

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
por: Kristeleit, Rebecca, et al.
Publicado: (2022)

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm
por: Goulden, Scott, et al.
Publicado: (2023)

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
por: Coleman, Robert L., et al.
Publicado: (2023)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Learning curve for laparoscopic staging of early and locally advanced cervical and endometrial cancer
por: Tahmasbi Rad, Morva, et al.
Publicado: (2013)

Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
por: Kobayashi, Monica, et al.
Publicado: (2023)

Endometrial hyperplasia as a risk factor of endometrial cancer
por: Nees, Lisa K., et al.
Publicado: (2022)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy
por: Ga, Hiromi, et al.
Publicado: (2023)

Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Wu, Pengfei, et al.
Publicado: (2022)

CD44 expression in curettage and postoperative specimens of endometrial cancer
por: Wojciechowski, Michał, et al.
Publicado: (2014)

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas
por: Zhan, Xiangbo, et al.
Publicado: (2019)

The sL1CAM in sera of patients with endometrial and ovarian cancers
por: Wojciechowski, Michał, et al.
Publicado: (2016)

Laparoscopic Indocyanine Green Sentinel Lymph Node Mapping in Endometrial Cancer
por: Papadia, Andrea, et al.
Publicado: (2016)

Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia
por: Girbash, Ehab F., et al.
Publicado: (2023)

Disparities in Timeliness of Endometrial Cancer Care: A Scoping Review
por: Najor, Anna, et al.
Publicado: (2023)

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer
por: Pignata, Sandro, et al.
Publicado: (2021)

Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma
por: Fujiwara, Kazuko, et al.
Publicado: (2011)

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer
por: Cornali, Tommaso, et al.
Publicado: (2017)

A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer
por: Wang, Tian, et al.
Publicado: (2019)

Association of polymorphisms in the 5′ untranslated region of RAD51 gene with risk of endometrial cancer in the Polish population
por: Michalska, Magdalena M., et al.
Publicado: (2014)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

Prospective Multicenter Trial Assessing the Impact of Positive Peritoneal Cytology Conversion on Oncological Outcome in Patients with Endometrial Cancer Undergoing Minimally Invasive Surgery with the use of an Intrauterine Manipulator: Positive Peritoneal Cytology Conversion and Its Association with Oncological Outcome in Endometrial Cancer
por: Siegenthaler, Franziska, et al.
Publicado: (2022)

Clinicopathological and molecular markers associated with prognosis and treatment effectiveness of endometrial stromal sarcoma: a retrospective study in China
por: He, Li, et al.
Publicado: (2013)

Patient-initiated follow-up of early endometrial cancer: a potential to improve post-treatment cardiovascular risk?
por: Johnson, Racheal Louise, et al.
Publicado: (2021)

Fertility preserving management of early endometrial cancer in a patient cohort at the department of women’s health at the university of Tuebingen
por: Andress, Jürgen, et al.
Publicado: (2021)

Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis
por: Travaglino, Antonio, et al.
Publicado: (2022)

Lymphedema after pelvic and para-aortic lymphadenectomy—results of a systematic evaluation in patients with cervical and endometrial carcinoma
por: Armbrust, R., et al.
Publicado: (2022)

Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer
por: Cabrera, Silvia, et al.
Publicado: (2023)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis
por: Ni, Liwei, et al.
Publicado: (2019)

Evolving trends in the surgical therapy of patients with endometrial cancer in Germany: analysis of a nationwide registry with special emphasis on perioperative outcomes
por: Roth, Katrin, et al.
Publicado: (2023)

A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer
por: Lavie, Ofer, et al.
Publicado: (2017)

Health-related quality of life after robotic surgery for endometrial cancer: a prospective longitudinal one-year follow-up study
por: Lindfors, Anna, et al.
Publicado: (2023)

Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer (99m)Tc and/or Blue Dye
por: Buda, Alessandro, et al.
Publicado: (2015)

Association of preoperative cone biopsy with recurrences after radical hysterectomy
por: Klapdor, Rüdiger, et al.
Publicado: (2021)

Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy
por: Kimmig, Rainer, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v6ivcq7ckok10qjnq7a8aumfjp